Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer

Hu,Changyuan; Chen,Renpin; Chen,Wenjing; Pang,Wenyang; Xue,Xiangyang; Zhu,Guangbao; Shen,Xian

doi:10.3892/etm.2014.1699

Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer

Authors:
- Changyuan Hu
- Renpin Chen
- Wenjing Chen
- Wenyang Pang
- Xiangyang Xue
- Guangbao Zhu
- Xian Shen
View Affiliations

Affiliations: Department of General Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Gastroenterology and Hepatology, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of General Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China, Department of Microbiology and Immunology, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: April 29, 2014 https://doi.org/10.3892/etm.2014.1699
Pages: 125-132

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although thrombocytosis has been reported in a variety of cancer types, the standard of thrombocytosis in gastric cancer (GC) and the association between thrombocytosis and the clinicopathological features of patients with GC remain unclear. In the present study, 1,763 GC patients were retrospectively filtered by preoperative thrombocytosis and compared with control group A (n=107) that had benign gastric lesions and control group B (n=100) that were GC patients with a normal platelet (PLT) count. Associations between clinical variables and preoperative PLT counts were assessed by univariate and multivariate analyses. Kaplan‑Meier survival curves and Cox regression were used to evaluate the effect of thrombocytosis on prognosis. Sensitivities and specificities of the PLT counts in predicting recurrence were analyzed via area under the receiver operating characteristic curve (AUROC). The results indicated that the incidence of thrombocytosis in GC patients was higher than in benign gastric lesion patients, with 4.03% of GC patients having a PLT count >400x109/l (P=0.014) and 12.08% had a PLT count >300x109/l (P<0.001). For the patients with a PLT count >400x109/l, the frequency of abnormal PLT counts in GC correlated with tumor size (P<0.001), tumor, node and metastasis (TNM) classification (P=0.002), invasive degree (P=0.003) and D‑dimer (P=0.013) and fibrinogen concentrations (P=0.042). Tumor size (P=0.002), TNM classification (P<0.001) and depth of penetration (P=0.001) were independent factors for thrombocytosis. However, thrombocytosis functioned as an independent prognostic factor for GC patients with a PLT count >400x109/l (relative risk, 1.538; 95% confidence interval, 1.041‑2.271). In the majority of patients (17/24) with a high preoperative PLT count that decreased to a normal level following resection, PLT levels increased again at recurrence. Sensitivities and specificities of thrombocytosis for recurrence in those patients were 70.8 and 83.3%, respectively (AUROC, 0.847; P=0.01). Therefore, a PLT count of 400x109/l is a suitable threshold for defining thrombocytosis in GC. Thrombocytosis was shown to affect the blood hypercoagulable state and also have a negative prognostic value for GC patients. PLT monitoring following surgery was useful to predict the recurrence for specific GC patients that suffered preoperative thrombocytosis but had restored PLT levels following resection.

View Figures

View References

1	Delhommeau F, Jeziorowska D, Marzac C and Casadevall N: Molecular aspects of myeloproliferative neoplasms. Int J Hematol. 91:165–173. 2010. View Article : Google Scholar
2	Gungor T, Kanat-Pektas M, Sucak A and Mollamahmutoglu L: The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet. 279:53–56. 2009. View Article : Google Scholar : PubMed/NCBI
3	Huang Z, Jiang C, Zhang YM and Yao B: Analysis of hemogram, iron staining in bone marrow and iron metabolism in 98 patients with thrombocytosis. Chinese Journal of Clinical Laboratory Science. 26:49–51. 2008.
4	Tchebiner JZ, Nutman A, Boursi B, et al: Diagnostic and prognostic value of thrombocytosis in admitted medical patients. Am J Med Sci. 342:395–401. 2011. View Article : Google Scholar : PubMed/NCBI
5	Iwasaki A, Hamanaka W, Harnada T, Maekawa S, Enatsu S and Shirakusa T: Significance of platelet counts in patients who underwent surgical treatment for lung metastasis. Int Surg. 92:103–109. 2007.PubMed/NCBI
6	Ikeda M, Furukawa H, Imamura H, et al: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 9:287–291. 2002. View Article : Google Scholar : PubMed/NCBI
7	Maráz A, Furák J, Varga Z, Kahán Z, Tiszlavicz L and Hideghéty K: Thrombocytosis has a negative prognostic value in lung cancer. Anticancer Res. 33:1725–1729. 2013.PubMed/NCBI
8	Gouin-Thibault I, Achkar A and Samama MM: The thrombophilic state in cancer patients. Acta Haematol. 106:33–42. 2001. View Article : Google Scholar
9	Riess L: Pathology of the blood. Arch Anat Physiol Wissensch Med. 39:237–249. 1872.(In German).
10	Ferrigno D and Buccheri G: Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis. 59:193–198. 2003.PubMed/NCBI
11	Qiu MZ, Xu RH, Ruan DY, et al: Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumour Biol. 31:633–641. 2010. View Article : Google Scholar : PubMed/NCBI
12	Aminian A, Karimian F, Mirsharifi R, et al: Significance of platelet count in esophageal carcinomas. Saudi J Gastroenterol. 17:134–137. 2011. View Article : Google Scholar : PubMed/NCBI
13	Aoe K, Hiraki A, Ueoka H, et al: Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration. 71:170–173. 2004. View Article : Google Scholar : PubMed/NCBI
14	Brockmann MA, Giese A, Mueller K, et al: Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro Oncol. 9:335–342. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nather A, Mayerhofer K, Grimm C, et al: Thrombocytosis and anaemia in women with recurrent ovarian cancer prior to a second-line chemotherapy. Anticancer Res. 23:2991–2994. 2003.PubMed/NCBI
16	Zwitter M, Kovac V, Smrdel U, Kocijancic I, Segedin B and Vrankar M: Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs. 16:1129–1134. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cerutti A, Custodi P, Duranti M, Noris P and Balduini CL: Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol. 99:281–284. 1997. View Article : Google Scholar : PubMed/NCBI
18	Soonthornthum T, Suraseraneewong V, Kengsakol K, Wijaithum K, Kasemsan P and Prommatt S: Thrombocytosis in advanced epithelial ovarian cancer. J Med Assoc Thai. 90:1495–1500. 2007.PubMed/NCBI
19	de Sauvage FJ, Carver-Moore K, Luoh SM, et al: Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med. 183:651–656. 1996.PubMed/NCBI
20	Lidor YJ, Xu FJ, Martínez-Maza O, et al: Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res. 207:332–339. 1993. View Article : Google Scholar : PubMed/NCBI
21	Ceresa IF, Noris P, Ambaglio C, Pecci A and Balduini CL: Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets. 18:579–582. 2007. View Article : Google Scholar : PubMed/NCBI
22	Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD and Petros JA: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 86:203–207. 2000. View Article : Google Scholar : PubMed/NCBI
23	Tomita M, Shimizu T, Ayabe T and Onitsuka T: Prognostic significance of the combined use of preoperative platelet count and serum carcinoembryonic antigen level in non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 58:573–576. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lian L, Li W, Li ZY, et al: Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Lett. 5:675–680. 2013.PubMed/NCBI
25	Palumbo JS, Talmage KE, Massari JV, et al: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 105:178–185. 2005. View Article : Google Scholar : PubMed/NCBI
26	McCarty OJ, Mousa SA, Bray PF and Konstantopoulos K: Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood. 96:1789–1797. 2000.PubMed/NCBI
27	Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A and Blay JY: Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 88:1721–1726. 2003. View Article : Google Scholar
28	Wang X, Chen X, Fang J and Yang C: Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol. 6:586–597. 2013.PubMed/NCBI